Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Drugs and their interactions.

Cokol M.

Curr Drug Discov Technol. 2013 Jun;10(2):106-13.

PMID:
23237673
2.

Analysis of drug interactions.

Bijnsdorp IV, Giovannetti E, Peters GJ.

Methods Mol Biol. 2011;731:421-34. doi: 10.1007/978-1-61779-080-5_34.

PMID:
21516426
3.

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.

Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, Langer E, Lude S, Hepp H, Pegram M.

Breast Cancer Res Treat. 2001 Jun;67(3):223-33.

PMID:
11561768
4.
5.

Combination bronchodilator therapy.

Shenfield GM.

Drugs. 1982 Nov;24(5):414-39. Review.

PMID:
6129123
6.

Optimizing combination chemotherapy by controlling drug ratios.

Mayer LD, Janoff AS.

Mol Interv. 2007 Aug;7(4):216-23. Review.

PMID:
17827442
7.

Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.

Fang HB, Tian GL, Li W, Tan M.

J Biopharm Stat. 2009 Jul;19(4):625-40. doi: 10.1080/10543400902964019.

PMID:
20183430
8.

Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.

Janss AJ, Cnaan A, Zhao H, Shpilsky A, Levow C, Sutton L, Phillips PC.

Anticancer Drugs. 1998 Aug;9(7):641-52.

PMID:
9773809
9.

Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.

Fang HB, Ross DD, Sausville E, Tan M.

Stat Med. 2008 Jul 20;27(16):3071-83. doi: 10.1002/sim.3204.

PMID:
18186545
10.

Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, Adams DJ.

Clin Cancer Res. 2005 Jun 1;11(11):4225-33.

11.

Drug interactions in the oncology patient.

Finley RS.

Semin Oncol Nurs. 1992 May;8(2):95-101. Review.

PMID:
1621008
12.

Multiple basis of combination chemotherapy.

Mihich E, Grindey GB.

Cancer. 1977 Jul;40(1 Suppl):534-43. Review.

13.

Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.

Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A.

Cell Death Differ. 2004 Jul;11(7):737-46.

14.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
15.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS.

Mol Cancer Ther. 2006 Jul;5(7):1854-63.

16.

[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Bret P, Bret MC, Queuille E.

Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7. French.

PMID:
19393381
17.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
18.

[Combined antimalarial therapy using artemisinin].

Majori G.

Parassitologia. 2004 Jun;46(1-2):85-7. Review. Italian.

PMID:
15305693
19.

[Drug interactions with anticancer agents].

Furue H.

Gan To Kagaku Ryoho. 1985 Dec;12(12):2231-6. Review. Japanese.

PMID:
3907502
20.

5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Zhou S, Kestell P, Baguley BC, Paxton JW.

Invest New Drugs. 2002 Aug;20(3):281-95. Review.

PMID:
12201491
Items per page

Supplemental Content

Write to the Help Desk